Healthcare Industry Update – 5th January 2022

Healthcare Industry Update – 5th January 2022

The importance of our worldwide healthcare sector has been magnified in recent years as we continue the battle against the COVID-19 pandemic. However, the sector also faces mounting pressures to address labour shortages while navigating an ever-changing healthcare situation. This exponential growth in healthcare activity has seen the demand for healthcare workers rise dramatically on a global scale.

Our previous healthcare industry update talked about how public hesitancy towards receiving the Covid-19 vaccination dramatically decreased over the past 12 months, leading Irish healthcare officials have reported that over 1 million doses of the booster vaccine have been administered in Ireland, and a coalition of doctors have called for the universal availability of free healthcare for those in need.

Here are the latest Healthcare Industry updates:

  • Ireland could experience an unwarranted rise in Covid-19 cases early this New Year as the more transmissible Omicron variant continues to have a large effect on the nation.
  • Irish citizens are set to receive greater and faster access to 35 new medicines for a range of medical conditions including, arthritis, psoriasis, various forms of cancer, and more in a new 4-year deal.
  • Paxlovid, possibly a worldwide game-changing drug in the fight against the Covid-19 pandemic is set to “be here in weeks” as it aims to lessen the effects of Covid-19.
  • A new society known as The Irish Society of Specialists in Public Health Medicine has been launched to act as a full-time advocacy board to Ireland’s full and part-time specialists (SPHM’s).
  • The HSE’s clinical lead in contract tracing, Greg Martin, has warned that worse “may be on the horizon” as it has become much more likely we will see another pandemic in our lifetime.

    Our team can be contacted at or call us at 051 355 704.

    Why not check out some of our latest news and healthcare industry updates, or follow us on LinkedIn.